MOUNTAIN VIEW, Calif., March 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today reported its financial results for the fourth quarter and year ended December 31, 2009. “This past year was transformational for VIVUS given the significant achievements in both the Qnexa and avanafil investigational product programs, which are being developed to address the obesity and erectile dysfunction markets with highly differentiated products that address unmet needs,” stated Leland Wilson, chief executive officer of VIVUS. “We look forward to continued clinical and regulatory momentum in 2010 as we continue to work with the FDA during the review of the Qnexa NDA and as we report additional avanafil pivotal data.”
